Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13326955 | 0.89 | KMT2A (1.00) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL11851842 | 0.89 | KMT2A (0.70) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL10278900 | 0.87 | KMT2A (0.68) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL5480430 | 0.87 | KMT2A (0.68) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL11898909 | 0.87 | KMT2A (0.68) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL11960321 | 0.84 | KMT2A (0.64) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL10847885 | 0.83 | KMT2A (0.62) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL24394696 | 0.82 | KMT2A (0.60) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL3113600 | 0.82 | KMT2A (0.60) | KMT2AALDH1A1NPSR1HRH4LMNA | |
| SCHEMBL13033934 | 0.80 | KMT2A (0.56) | KMT2AALDH1A1NPSR1HRH4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019101853-A1 | TREATMENT OF SKIN DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2019-05-31 | — | — | WO | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-2819996-B1 | 6-ALKYNYL PYRIDINES AS SMAC MIMETICS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-04 | — | — | EP | disclosed |
| US-9309240-B2 | Pyrazolopyridine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015200680-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-2640722-B1 | PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-11-04 | — | — | EP | disclosed |
| WO-2015091584-A1 | THIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS TYK2 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| EP-2819996-A1 | 6 - ALKYNYL PYRIDINES AS SMAC MIMETICS | Boehringer Ingelheim International GmbH (DE) | 2015-01-07 | — | — | EP | disclosed |
| CN-104169257-A | 6-alkynyl-pyridines as SMAC mimetics | BOEHRINGER INGELHEIM INT | 2014-11-26 | — | — | CN | disclosed |
| US-8859541-B2 | 6-alkynylpyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20100137311-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2010-06-03 | — | — | US | disclosed |
| US-7683058-B2 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2010-03-23 | — | — | US | disclosed |
| US-7683058-B2 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2010-03-23 | — | — | US | disclosed |
| US-7683058-B2 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2010-03-23 | — | — | US | disclosed |
| EP-1937653-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H.Lundbeck A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066612-A1 | Substituted pyrimidine derivatives | DPYD, TYMP, TYMS | KMT2A 3194/4885ALDH1A1 641/4885NPSR1 3170/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | KMT2A 60/4885ALDH1A1 3367/4885NPSR1 4675/4885 |
| US-20100137311-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | DPYD, TYMP, TYMS | KMT2A 3194/4885ALDH1A1 641/4885NPSR1 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.